KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Equity Average (2018 - 2025)

Bionano Genomics' Equity Average history spans 7 years, with the latest figure at $47.6 million for Q3 2025.

  • For Q3 2025, Equity Average fell 26.34% year-over-year to $47.6 million; the TTM value through Sep 2025 reached $47.6 million, down 26.34%, while the annual FY2024 figure was $65.8 million, 61.94% down from the prior year.
  • Equity Average for Q3 2025 was $47.6 million at Bionano Genomics, up from $46.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $354.3 million in Q2 2021 and bottomed at $41.8 million in Q1 2025.
  • The 5-year median for Equity Average is $198.9 million (2021), against an average of $187.3 million.
  • The largest annual shift saw Equity Average soared 66400.0% in 2021 before it plummeted 63.45% in 2024.
  • A 5-year view of Equity Average shows it stood at $339.3 million in 2021, then fell by 21.74% to $265.6 million in 2022, then plummeted by 59.49% to $107.6 million in 2023, then plummeted by 60.85% to $42.1 million in 2024, then rose by 12.98% to $47.6 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Equity Average are $47.6 million (Q3 2025), $46.8 million (Q2 2025), and $41.8 million (Q1 2025).